Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant

Kyungpook National University Hospital88 enrolled

Overview

The purpose of this study was to compare the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in high risk patients undergoing laparoscopic cholecystectomy.

The purpose of this study was to compare the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in high risk patients undergoing laparoscopic cholecystectomy. Study is performed during 24 hours after surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

Postoperative Nausea and Vomiting

Interventions

aprepitantDRUG

aprepitant 80 mg is given to all patients before surgery

palonosetronDRUG

palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia

RamosetronDRUG

ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non smoking, female patients, scheduled for laparoscopic cholecystectomy Exclusion Criteria: * Patients with gastrointestinal disorder, * Patients with allergies to any study medication, * Patients who had received any sedatives, opioid, steroid or antiemetics within 24 h before surgery

Outcomes

Primary Outcomes

The Incidence of Postoperative Nausea and Vomiting

The incidence of postoperative nausea and vomiting during 24 hours postoperatively

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.